Author's response to reviews

Size: px
Start display at page:

Download "Author's response to reviews"

Transcription

1 Author's response to reviews Title:Randomized Phase III Trial of Radiotherapy or Chemoradiotherapy With Topotecan and Cisplatin in Intermediate-Risk Cervical Cancer Patients After Radical Hysterectomy Authors: Wenze Sun Tao Wang Fan Shi Jiquan Wang Juan Wang Beina Hui Yingbing Zhang Jinli Lu Hongwei Chen Zi Liu Version:4Date:31 March 2015 Author's response to reviews: see over

2 Author's response to reviews Title: Randomized Phase III Trial of Radiotherapy or Chemoradiotherapy With Topotecan and Cisplatin in Intermediate-Risk Cervical Cancer Patients After Radical Hysterectomy Authors: Wenze Sun Tao Wang Fan Shi Jiquan Wang Juan Wang Beina Hui Yingbing Zhang Jinli Lu Hongwei Chen Zi Liu Version: 2 Date: 31 March 2015 Author's response to reviews: see over

3 Dear Editor: Thank you for the feedback. I am very grateful for your advice and reviewers comments about our manuscript (Randomized Phase III Trial of Radiotherapy or Chemoradiotherapy With Topotecan and Cisplatin in Intermediate-Risk Cervical Cancer Patients After Radical Hysterectomy. MS: ). In response to the comments and advices, we have revised our manuscript. Here are the point-to-point responses to the reviewers comments: Reviewer # 1 ( Dr Giulia Amadio): We first thank for the positive comments 1-5, 8 and10 of Giulia Amadio. 6 The discussion and conclusions are well balanced and adequately supported by the data but the limitations of the work are not clearly stated in the paper; a longer follow up period could be useful to report survival data. Revision: We have stated the limitations of the study in the discussion part of revised paper. It could be seen in lines 268 to 275 on page 7: Although our study showed severe hematologic toxicity of concurrent chemoradiation with topotecan and cisplatin in safe dose to radiation in patients with intermediate-risk factors, the efficacy and toxicity are still unclear. As we mentioned in the results, the number of patients in the different group is small (14 in group A, 15 in group B and 10 in group C) because the study closed ahead of schedule and the media follow-up time is only 16 months. In spite of these limitations, due to topotecan has been identificated as an antineoplastic agent with cisplatin in cervival cancer, a trial with optimal dose,sufficient size and long term follow-up would be necessary to demonstrate the advantage of concurrent chemoradiation in patients with intermediate-risk factors. 7 authors may report : Postoperative pelvic intensity-modulated radiotherapy and concurrent chemotherapy in intermediate- and high-risk cervical cancer. Folkert MR, Shih KK, Abu-Rustum NR, Jewell E, Kollmeier MA, Makker V, Barakat RR, Alektiar KM. Gynecol Oncol Feb;128(2): doi: /j.ygyno Epub 2012 Nov 15. Impact of the addition of concurrent chemotherapy to pelvic radiotherapy in surgically treated stage IB1-IIB cervical cancer patients with intermediate-risk or high-risk factors: a 13-year experience. Okazawa M, Mabuchi S, Isohashi F, Suzuki O, Yoshioka Y, Sasano T, Ohta Y,Kamiura S, Ogawa K, Kimura T. Int J Gynecol Cancer Mar;23(3): Role of adjuvant radiotherapy after radical hysterectomy in node-negative stage IB-IIA cervical cancer with intermediate risk factors.tuipae S, Yanaranop M, Oniem N.J Med Assoc Thai Mar;95 Suppl 3:S Revision: We have reported the studies in our revised discussion in lines 196 to 197 and lines 205 to 210 on page 6. Lines : In addition, in the study of Tuipae S et al, distant recurrence was still the major pattern of treatment failure after adjuvant radiotherapy in cervical cancer with intermediate risk factors[12]. Lines : Okazawa M et al reviewed the medical records of 316 patients with stage

4 IB1-IIB cervical cancer who had been treated with adjuvant radiotherapy (RT) (n = 124, RT group) or adjuvant CCRT (n = 192, CCRT group) after radical hysterectomy and found that CCRT was superior to RT with regard to recurrence rate and PFS in patents with 2 or more intermediate risk factors, while the patients with only 1 intermediate risk factor showed no survival benefit of CCRT over RT[20]. Reviewer # 2 (Dr Giacomo Corrado): We also first thank for the comments of Giacomo Corrado. 1 The number of patients in the different group is very small in order to express any conclusion. Revision: We aimed to report that, although topotecan with cisplatin has been shown acceptable toxicity and good response rates in recurrent or metastatic cervical cancer, topotecan plus cisplatin chemotherapy in safe dose with RT in present study showed severe hematologic toxicity and the study was closed ahead of schedule. Therefore, the number of enrolled patients was small which may have resulted in study data bias. Trials with optimal dose,sufficient size and long term follow-up would be carried out to demonstrate the advantage of concurrent chemoradiation with topotecan and cisplatin in patients with intermediate-risk factors in the following time. 2 Authors should explain what kind of radical surgery performed in these patients. Revision: We have explained what kind of radical surgery performed in these patients in lines 99 to 101 on page 3: Radical hysterectomy and pelvic lymphadenectomy, with or without para-aortic lymphadenectomy was performed either via laparotomy or laparoscopy, according to the Gynecologic Procedures Manual of the GOG, which outlined minimum surgical requirements for study entry[15]. 3 Authors should explain the scientific basis on which they wanted to create the group C. Authors report 20 IB2 and 10 IIA in their study. Why these patients have not been treated with RTCT neoadjuvant or exclusive? In fact, these treatments are considered the first choice in these patients. Revision: We have explained the scientific basis on which we wanted to create the group C in our revised discussion on pages 6-7. Recently, cisplatin-based consolidation chemotherapy after CCRT has been reported to enhance local control and promote eradication of possible distant micro-metastases in locally advanced cervical cancer by phase II studies [1-3]. These promising results suggested that consolidation chemotherapy after primary CCRT may play a role independent of the radiotherapy in locally advanced cervical carcinoma. Furthermore, for high-risk patients after radical surgery, whether consolidation chemotherapy after CCRT could improve PFS and OS as compared to CCRT-only is controversial [4-5]. However, to date, no study has looked at the role of consolidation chemotherapy following CCRT in intermediate-risk cervical cancer patients? We designed arm C (CCRT+CT) to examine whether the addition of consolidation chemotherapy to CCRT could improve the PFS and OS in patients with intermediate-risk factors after radical surgery.

5 References: 1. Vrdoljak E, Prskalo T, Omrcen T, Situm K, Boraska T, Frleta Ilić N, Janković S, Hamm W:Concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by consolidation chemotherapy in locally advanced squamous cell carcinoma of the uterine cervix: results of a phase II study. Int J Radiat Oncol Biol Phys. 2005, 61: Zhang MQ, Liu SP, Wang XE: Concurrent chemoradiotherapy with paclitaxel and nedaplatin followed by consolidation chemotherapy in locally advanced squamous cell carcinoma of the uterine cervix: preliminary results of a phase II study. Int J Radiat Oncol Biol Phys. 2010, 78: Choi CH, Lee YY, Kim MK, Kim TJ, Lee JW, Nam HR, Huh SJ, Lee JH, Bae DS, Kim BG: A matched-case comparison to explore the role of consolidation chemotherapy after concurrent chemoradiation in cervical cancer. Int J Radiat Oncol Biol Phys. 2011, 81: Peters 3rd WA, Liu PY, Barrett 2nd RJ, Stock RJ, Monk BJ, Berek JS, Souhami L, Grigsby P, Gordon W Jr, Alberts DS: Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000, 18: Kim HS, Kim MK, Kim HJ, Han SS, Kim JW: Phase II Study of Consolidation Chemotherapy after Adjuvant or Primary Concurrent Chemoradiation Using Paclitaxel and Carboplatin to Treat High-Risk Early-Stage or Locally Advanced Cervical Cancer. Cancer Res Treat. 2012, 44: According to NCCN guideline, definitive concurrent chemoradiotherapy is considered to be the first choice for stage IB2 and IIA2 cervical cancer (category 1). But at the same time, radical surgery followed by adjuvant therapy has also been accepted as the treatment in patients with stage IB2 and IIA2 cervical cancer (category 2B). In China, not every medical institution could perform definitive radiotherapy. Therefore, they may first choose the radical surgery for stage IB2 and IIA2 cervical cancer according to their own ability. 4 To improve the quality of the study, the authors should perform a review of published works on the subject with careful attention to the impact on the survival of the different treatments performed. Revision: In our revised discussion on page 6(lines 199 to 210),some retrospective studies in recent years have showed adjuvant CCRT was superior to RT with regard to RFS (recurrence-free survival) or PFS in patients with intermediate-risk factors[1-5]. However, due to the lack of randomized trials,whether adjuvant CCRT or adjuvant CCRT followed by consolidation chemotherapy could improve PFS and OS in patients with intermediate-risk factors is still unclear. On account of the scientific basis, we wanted to carry out the present study. We will perform a review of studies on the subject with careful attention to the impact on the survival of the different treatments performed in the following time. References: 1. Soisson AP, Soper JT, Clarke-Pearson DL, Berchuck A, Montana G, Creasman WT: Adjuvant radiotherapy following radical hysterectomy for patients with stage IB and IIA cervical cancer. Gynecol Oncol 1990, 37: Kim K, Kang SB, Chung HH, Kim JW, Park NH, Song YS: Comparison of chemoradiation with radiation as postoperative adjuvant therapy in cervical cancer patients with intermediate-risk factors. Eur J Surg Oncol 2009, 35: Ryu SY, Park SI, Nam BH, Cho CK, Kim K, Kim BJ, Kim MH, Choi SC, Lee ED, Lee KH: Is adjuvant chemoradiotherapy overtreatment in cervical cancer patients with intermediate risk factors? Int J Radiat Oncol Biol Phys 2011, 79: Lee TY, Jeung YJ, Lee CJ, Kim HY, Kim SH, Kim WG: Promising treatment results of adjuvant chemotherapy following

6 radical hysterectomy for intermediate risk stage 1B cervical cancer. Obstet Gynecol Sci 2013, 56: Okazawa M, Mabuchi S, Isohashi F, Suzuki O, Yoshioka Y, Sasano T, Ohta Y, Kamiura S, Ogawa K, Kimura T: Impact of the addition of concurrent chemotherapy to pelvic radiotherapy in surgically treated stage IB1-IIB cervical cancer patients with intermediate-risk or high-risk factors: a 13-year experience. Int J Gynecol Cancer. 2013, 23: All changes made when revising the manuscript have been highlighted with red colored letters. Yours sincerely, Wenze Sun, Zi Liu

Wenze Sun, Tao Wang, Fan Shi, Jiquan Wang, Juan Wang, Beina Hui, Yingbing Zhang, Jinli Lu, Hongwei Chen and Zi Liu *

Wenze Sun, Tao Wang, Fan Shi, Jiquan Wang, Juan Wang, Beina Hui, Yingbing Zhang, Jinli Lu, Hongwei Chen and Zi Liu * Sun et al. BMC Cancer (2015) 15:353 DOI 10.1186/s12885-015-1355-1 RESEARCH ARTICLE Open Access Randomized phase III trial of radiotherapy or chemoradiotherapy with topotecan and cisplatin in intermediate-risk

More information

Concurrent chemoradiation in treatment of carcinoma cervix

Concurrent chemoradiation in treatment of carcinoma cervix N. J. Obstet. Gynaecol Vol. 2, No. 1, p. 4-8 May -June 2007 REVIEW Concurrent chemoradiation in treatment of carcinoma cervix Meeta Singh, Rajshree Jha, Josie Baral, Suniti Rawal Dept of Obs/Gyn, TU Teaching

More information

RESEARCH ARTICLE. Ai-Qiu Qin 1&, Zhong-Guo Liang 2&, Jia-Xiang Ye 3 *, Jing Li 1, Jian-Li Wang 1, Chang-Xian Chen 1, Hong-Lin Song 1 * Abstract

RESEARCH ARTICLE. Ai-Qiu Qin 1&, Zhong-Guo Liang 2&, Jia-Xiang Ye 3 *, Jing Li 1, Jian-Li Wang 1, Chang-Xian Chen 1, Hong-Lin Song 1 * Abstract 10.14456/apjcp.2016.196/APJCP.2016.17..3945 RESEARCH ARTICLE Significant Efficacy of Additional Concurrent Chemotherapy with Radiotherapy for Postoperative Cervical Cancer with Risk Factors: a Systematic

More information

UPDATE IN THE MANAGEMENT OF INVASIVE CERVICAL CANCER

UPDATE IN THE MANAGEMENT OF INVASIVE CERVICAL CANCER UPDATE IN THE MANAGEMENT OF INVASIVE CERVICAL CANCER Susan Davidson, MD Professor Department of Obstetrics and Gynecology Division of Gynecologic Oncology University of Colorado- Denver Anatomy Review

More information

ORIGINAL PAPER. Department of Radiology, Nagoya University Graduate School of Medicine, Aichi, Japan 2

ORIGINAL PAPER. Department of Radiology, Nagoya University Graduate School of Medicine, Aichi, Japan 2 Nagoya J. Med. Sci. 79. 211 ~ 220, 2017 doi:10.18999/nagjms.79.2.211 ORIGINAL PAPER Postoperative chemoradiation therapy using high dose cisplatin and fluorouracil for high- and intermediate-risk uterine

More information

Chapter 8 Adenocarcinoma

Chapter 8 Adenocarcinoma Page 80 Chapter 8 Adenocarcinoma Overview In Japan, the proportion of squamous cell carcinoma among all cervical cancers has been declining every year. In a recent survey, non-squamous cell carcinoma accounted

More information

Prognostic significance of positive lymph node number in early cervical cancer

Prognostic significance of positive lymph node number in early cervical cancer 1052 Prognostic significance of positive lymph node number in early cervical cancer JUNG WOO PARK and JONG WOON BAE Department of Obstetrics and Gynecology, Dong A University Hospital, Dong A University

More information

Management of high risk early cervical cancer - a view of surgeon Dan DY Kim, M.D., Ph.D.

Management of high risk early cervical cancer - a view of surgeon Dan DY Kim, M.D., Ph.D. Management of high risk early cervical cancer - a view of surgeon Dan DY Kim, M.D., Ph.D. Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea

More information

receive adjuvant chemotherapy

receive adjuvant chemotherapy Women with high h risk early stage endometrial cancer should receive adjuvant chemotherapy Michael Friedlander The Prince of Wales Cancer Centre and Royal Hospital for Women The Prince of Wales Cancer

More information

Weekly Versus Triweekly Cisplatin-Based Chemotherapy Concurrent With Radiotherapy in the Treatment of Cervical Cancer

Weekly Versus Triweekly Cisplatin-Based Chemotherapy Concurrent With Radiotherapy in the Treatment of Cervical Cancer REVIEW ARTICLE Weekly Versus Triweekly Cisplatin-Based Chemotherapy Concurrent With Radiotherapy in the Treatment of Cervical Cancer A Meta-Analysis Xingxing Chen, MD,* Haizhou Zou, MD,Þ Huifang Li, MD,*

More information

Lei Li 1*, XiaoYan Song 2, RuoNan Liu 1, Nan Li 1, Ye Zhang 1, Yan Cheng 1, HongTu Chao 1 and LiYing Wang 1

Lei Li 1*, XiaoYan Song 2, RuoNan Liu 1, Nan Li 1, Ye Zhang 1, Yan Cheng 1, HongTu Chao 1 and LiYing Wang 1 Li et al. BMC Cancer (2016) 16:403 DOI 10.1186/s12885-016-2447-2 RESEARCH ARTICLE Open Access Chemotherapy versus radiotherapy for FIGO stages IB1 and IIA1 cervical carcinoma patients with postoperative

More information

ONCOLOGY LETTERS 3: , 2012

ONCOLOGY LETTERS 3: , 2012 ONCOLOGY LETTERS 3: 641-645, 2012 Treatment of early bulky cervical cancer with neoadjuvant paclitaxel, carboplatin and cisplatin prior to laparoscopical radical hysterectomy and pelvic lymphadenectomy

More information

RESEARCH ARTICLE. Kuanoon Boupaijit, Prapaporn Suprasert* Abstract. Introduction. Materials and Methods

RESEARCH ARTICLE. Kuanoon Boupaijit, Prapaporn Suprasert* Abstract. Introduction. Materials and Methods RESEARCH ARTICLE Survival Outcomes of Advanced and Recurrent Cervical Cancer Patients Treated with Chemotherapy: Experience of Northern Tertiary Care Hospital in Thailand Kuanoon Boupaijit, Prapaporn Suprasert*

More information

Gynecologic Cancer InterGroup Cervix Cancer Research Network. Management of Cervical Cancer in Resource Limited Settings.

Gynecologic Cancer InterGroup Cervix Cancer Research Network. Management of Cervical Cancer in Resource Limited Settings. Management of Cervical Cancer in Resource Limited Settings Linus Chuang MD Conflict of Interests None Cervical cancer is the fourth most common malignancy in women worldwide 530,000 new cases per year

More information

Chapter 5 Stage III and IVa disease

Chapter 5 Stage III and IVa disease Page 55 Chapter 5 Stage III and IVa disease Overview Concurrent chemoradiotherapy (CCRT) is recommended for stage III and IVa disease. Recommended regimen for the chemotherapy portion generally include

More information

Adjuvant Therapies in Endometrial Cancer. Emma Hudson

Adjuvant Therapies in Endometrial Cancer. Emma Hudson Adjuvant Therapies in Endometrial Cancer Emma Hudson Endometrial Cancer Most common gynaecological cancer Incidence increasing in Western world 1-2% cancer deaths 75% patients postmenopausal 97% epithelial

More information

Update on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer

Update on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer Update on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy NACT in Cervical Cancer NACT Stage -IB2 -IIA>4cm

More information

Chun-Chieh Wang, MD and Feng-Yuan Liu, MD/ Prof. Chyong-Huey Lai, MD

Chun-Chieh Wang, MD and Feng-Yuan Liu, MD/ Prof. Chyong-Huey Lai, MD Concept/trial design presentation A Phase 2 Trial of Pembrolizumab Combined with Chemoradiation for Patients with [ 18 F]-FDG PET/CT-defined Poor-prognostic Cervical Cancer Chun-Chieh Wang, MD and Feng-Yuan

More information

Chemotherapy for Cervical Cancer. Matsue City Hospital Junzo Kigawa

Chemotherapy for Cervical Cancer. Matsue City Hospital Junzo Kigawa Chemotherapy for Cervical Cancer Matsue City Hospital Junzo Kigawa Introduction Worldwide, cervical cancer is the second most common cancer in women and affects 530,000 new patients and 275,000 deaths.

More information

PROMISING TREATMENT RESULTS OF ADJUVANT CHEMOTHERAPY FOLLOWING RADICAL HYSTERECTOMY FOR INTERMEDIATE RISK STAGE 1B CERVICAL CANCER

PROMISING TREATMENT RESULTS OF ADJUVANT CHEMOTHERAPY FOLLOWING RADICAL HYSTERECTOMY FOR INTERMEDIATE RISK STAGE 1B CERVICAL CANCER ORIGINAL ARTICLE Obstet Gynecol Sci 2013;56(1):15-21 http://dx.doi.org/10.5468/ogs.2013.56.1.15 pissn 2287-8572 eissn 2287-8580 PROMISING TREATMENT RESULTS OF ADJUVANT CHEMOTHERAPY FOLLOWING RADICAL HYSTERECTOMY

More information

A phase II study of weekly paclitaxel and cisplatin followed by radical hysterectomy in stages IB2 and IIA2 cervical cancer AGOG14-001/TGOG1008

A phase II study of weekly paclitaxel and cisplatin followed by radical hysterectomy in stages IB2 and IIA2 cervical cancer AGOG14-001/TGOG1008 A phase II study of weekly paclitaxel and cisplatin followed by radical hysterectomy in stages IB2 and IIA2 cervical cancer AGOG14-001/TGOG1008 NCT02432365 Chyong-Huey Lai, MD On behalf of Principal investigator

More information

Original Article. Introduction. Soyi Lim 1, Seok-Ho Lee 2, Kwang Beom Lee 1, Chan-Yong Park 1

Original Article. Introduction. Soyi Lim 1, Seok-Ho Lee 2, Kwang Beom Lee 1, Chan-Yong Park 1 Original Article Obstet Gynecol Sci 2016;59(3):184-191 http://dx.doi.org/10.5468/ogs.2016.59.3.184 pissn 2287-8572 eissn 2287-8580 The influence of number of high risk factors on clinical outcomes in patients

More information

GCIG Rare Tumour Brainstorming Day

GCIG Rare Tumour Brainstorming Day GCIG Rare Tumour Brainstorming Day Relatively (Not So) Rare Tumours Adenocarcinoma of Cervix Keiichi Fujiwara, Ros Glasspool Benedicte Votan, Jim Paul Aim of the Day To develop at least one clinical trial

More information

Original Article. Introduction. Tae-Kyu Jang, So-Jin Shin, Hyewon Chung, Sang-Hoon Kwon, Soon-Do Cha, Eunbi Lee, Changmin Shin, Chi-Heum Cho

Original Article. Introduction. Tae-Kyu Jang, So-Jin Shin, Hyewon Chung, Sang-Hoon Kwon, Soon-Do Cha, Eunbi Lee, Changmin Shin, Chi-Heum Cho Original Article Obstet Gynecol Sci 2017;60(6):549-557 https://doi.org/10.5468/ogs.2017.60.6.549 pissn 2287-8572 eissn 2287-8580 A retrospective comparison of outcome in IB2 and IIA cervical cancer patients

More information

Role of Surgery in Cervical Cancer & Research Questions

Role of Surgery in Cervical Cancer & Research Questions Role of Surgery in Cervical Cancer & Research Questions Arb-aroon Lertkhachonsuk, M.D., Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand Role of surgery in cervical cancer

More information

The clinicopathological features and treatment modalities associated with survival of neuroendocrine cervical carcinoma in a Chinese population

The clinicopathological features and treatment modalities associated with survival of neuroendocrine cervical carcinoma in a Chinese population Zhang et al. BMC Cancer (2019) 19:22 https://doi.org/10.1186/s12885-018-5147-2 RESEARCH ARTICLE Open Access The clinicopathological features and treatment modalities associated with survival of neuroendocrine

More information

Comparison of concurrent chemoradiation therapy with weekly cisplatin versus monthly fluorouracil plus cisplatin in FIGO stage IIB-IVA cervical cancer

Comparison of concurrent chemoradiation therapy with weekly cisplatin versus monthly fluorouracil plus cisplatin in FIGO stage IIB-IVA cervical cancer Original Article J Gynecol Oncol Vol. 23, No. 4:235-241 pissn 2005-0380 eissn 2005-0399 Comparison of concurrent chemoradiation therapy with weekly cisplatin versus monthly fluorouracil plus cisplatin

More information

Int J Clin Exp Med 2015;8(9): /ISSN: /IJCEM Du He, Chunyan Duan, Jun Chen, Lin Lai, Jiaquan Chen, Dian Chen

Int J Clin Exp Med 2015;8(9): /ISSN: /IJCEM Du He, Chunyan Duan, Jun Chen, Lin Lai, Jiaquan Chen, Dian Chen Int J Clin Exp Med 2015;8(9):14693-14700 www.ijcem.com /ISSN:1940-5901/IJCEM0008961 Original Article The safety and efficacy of the preoperative neoadjuvant chemotherapy for patients with cervical cancer:

More information

Prognostic factors and treatment outcome after radiotherapy in cervical cancer patients with isolated para-aortic lymph node metastases

Prognostic factors and treatment outcome after radiotherapy in cervical cancer patients with isolated para-aortic lymph node metastases Original Article J Gynecol Oncol Vol. 24, No. 3:229-235 pissn 2005-0380 eissn 2005-0399 Prognostic factors and treatment outcome after radiotherapy in cervical cancer patients with isolated para-aortic

More information

Adjuvant chemotherapy for early-stage cervical cancer

Adjuvant chemotherapy for early-stage cervical cancer Review Article on Cervical Cancer Adjuvant chemotherapy for early-stage cervical cancer Hiroshi Asano 1, Yukiharu Todo 2, Hidemichi Watari 1 1 Department of Obstetrics and Gynecology, Hokkaido University

More information

The relationship between positive peritoneal cytology and the prognosis of patients with FIGO stage I/II uterine cervical cancer

The relationship between positive peritoneal cytology and the prognosis of patients with FIGO stage I/II uterine cervical cancer Original Article J Gynecol Oncol Vol. 25,. 2:9-96 http://dx.doi.org/.382/jgo.24.25.2.9 pissn 25-38 eissn 25-399 The relationship between positive peritoneal cytology and the prognosis of patients with

More information

Nordic Society for Gynecological Oncology Advisory Board of Radiotherapy

Nordic Society for Gynecological Oncology Advisory Board of Radiotherapy Nordic Society for Gynecological Oncology Advisory Board of Radiotherapy Guidelines for postoperative irradiation of cervical cancer Contents: 1. Treatment planning for EBRT. 2 2. Target definition for

More information

Intra-operative frozen section analysis of common iliac lymph nodes in patients with stage IB1 and IIA1 cervical cancer

Intra-operative frozen section analysis of common iliac lymph nodes in patients with stage IB1 and IIA1 cervical cancer Arch Gynecol Obstet (2012) 285:811 816 DOI 10.1007/s00404-011-2038-z GYNECOLOGIC ONCOLOGY Intra-operative frozen section analysis of common iliac lymph nodes in patients with stage IB1 and IIA1 cervical

More information

surgical staging g in early endometrial cancer

surgical staging g in early endometrial cancer Risk adapted d approach to surgical staging g in early endometrial cancer Leon Massuger University Medical Centre St Radboud Nijmegen, The Netherlands Doing nodes Yes Yes Yes No No No 1957---------------------------

More information

17 th ESO-ESMO Masterclass in clinical Oncology

17 th ESO-ESMO Masterclass in clinical Oncology 17 th ESO-ESMO Masterclass in clinical Oncology Cervical and endometrial Cancer Cristiana Sessa IOSI Bellinzona, Switzerland Berlin, March 28 th, 2018 Presenter Disclosures None Cervical Cancer Estimated

More information

Concurrent chemoradiotherapy with low-dose daily cisplatin for high risk uterine cervical cancer: a long-term follow-up study

Concurrent chemoradiotherapy with low-dose daily cisplatin for high risk uterine cervical cancer: a long-term follow-up study Original Article J Gynecol Oncol Vol. 24, No. 2:108-113 http://dx.doi.org/10.3802/jgo.2013.24.2.108 pissn 2005-0380 eissn 2005-0399 Concurrent chemoradiotherapy with low-dose daily cisplatin for high risk

More information

: Ajou University College of Medicine, Suwon, Korea; Ajou University College of Medicine, Graduate

: Ajou University College of Medicine, Suwon, Korea; Ajou University College of Medicine, Graduate CURRICULUM VITAE NAME Hyun Woo Lee, M.D. EDUCATION 1991.3.-2001.2 : Ajou University College of Medicine, Suwon, Korea; Doctor of Medicine 2004.3-2006.2 Ajou University College of Medicine, Graduate School,

More information

Winship Cancer Institute of Emory University Optimizing First Line Treatment of Advanced Ovarian Cancer

Winship Cancer Institute of Emory University Optimizing First Line Treatment of Advanced Ovarian Cancer Winship Cancer Institute of Emory University Optimizing First Line Treatment of Advanced Ovarian Cancer Ira R. Horowitz, MD, SM, FACOG, FACS John D. Thompson Professor and Chairman Department of Gynecology

More information

Locally advanced disease & challenges in management

Locally advanced disease & challenges in management Gynecologic Cancer InterGroup Cervix Cancer Research Network Cervix Cancer Education Symposium, February 2018 Locally advanced disease & challenges in management Carien Creutzberg Radiation Oncology, Leiden

More information

Prognosis and recurrence pattern of patients with cervical carcinoma and pelvic lymph node metastasis

Prognosis and recurrence pattern of patients with cervical carcinoma and pelvic lymph node metastasis NJOG 2009 June-July; 4 (1): 19-24 Prognosis and recurrence pattern of patients with cervical carcinoma and pelvic lymph node metastasis Eliza Shrestha 1, Xiong Ying 1,2, Liang Li-Zhi 1,2, Zheng Min 1,2,

More information

ECC or Margins Positive?

ECC or Margins Positive? CLINICAL PRESENTATION This practice algorithm has been specifically developed for M. D. Anderson using a multidisciplinary approach and taking into consideration circumstances particular to M. D. Anderson,

More information

Ke Hu, Weiping Wang, Xiaoliang Liu, Qingyu Meng and Fuquan Zhang *

Ke Hu, Weiping Wang, Xiaoliang Liu, Qingyu Meng and Fuquan Zhang * Hu et al. Radiation Oncology (2018) 13:249 https://doi.org/10.1186/s13014-018-1197-5 RESEARCH Open Access Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma of cervix after

More information

Outcomes and prognostic factors of cervical cancer after concurrent chemoradiationjog_

Outcomes and prognostic factors of cervical cancer after concurrent chemoradiationjog_ bs_bs_banner doi:10.1111/j.1447-0756.2012.01871.x J. Obstet. Gynaecol. Res. Vol. 38, No. 11: 1315 1320, November 2012 Outcomes and prognostic factors of cervical cancer after concurrent chemoradiationjog_1871

More information

GCIG Cervix Committee: Chicago, USA May 30th Satoru Sagae (JGOG) Bradley Monk (GOG)

GCIG Cervix Committee: Chicago, USA May 30th Satoru Sagae (JGOG) Bradley Monk (GOG) GCIG Cervix Committee: Chicago, USA May 30th 2013 Satoru Sagae (JGOG) Bradley Monk (GOG) Conflict of Interest Disclosures CURRENT ACTIVE/NEAR ACTIVATION RANDOMIZED TRIALS WITH GCIG PARTICIPATION: Wellcome

More information

Update on Sentinel Node Biopsy in Endometrial Cancer: Feasibility, Technique, Impact

Update on Sentinel Node Biopsy in Endometrial Cancer: Feasibility, Technique, Impact Update on Sentinel Node Biopsy in Endometrial Cancer: Feasibility, Technique, Impact Bjørn Hagen, MD, PhD St Olavs Hospital Trondheim University Hospital Trondheim, Norway Endometrial Cancer (EC) The most

More information

Title: Positron Emission Tomography (PET) for Staging Cervical Cancer: Clinical Effectiveness and Guidelines for Use

Title: Positron Emission Tomography (PET) for Staging Cervical Cancer: Clinical Effectiveness and Guidelines for Use Title: Positron Emission Tomography (PET) for Staging Cervical Cancer: Clinical Effectiveness and Guidelines for Use Date: 16 July 2008 Research question: 1. What is the clinical effectiveness of positron

More information

Is Ovarian Preservation Feasible in Early-Stage Adenocarcinoma of the Cervix?

Is Ovarian Preservation Feasible in Early-Stage Adenocarcinoma of the Cervix? e-issn 1643-3750 DOI: 10.12659/MSM.897291 Received: 2015.12.27 Accepted: 2016.01.13 Published: 2016.02.08 Is Ovarian Preservation Feasible in Early-Stage Adenocarcinoma of the Cervix? Authors Contribution:

More information

Evolving Treatment Strategies for Cervical Cancer

Evolving Treatment Strategies for Cervical Cancer Evolving Treatment Strategies for Cervical Cancer Nadeem Abu-Rustum, MD Memorial Sloan Kettering Cancer Center Evolving Treatment Strategies 1. Surgery 2. Radiation 3. Chemotherapy Incidence of cervix

More information

Management of Cervical Cancer in Resource Limited Settings

Management of Cervical Cancer in Resource Limited Settings Management of Cervical Cancer in Resource Limited Settings Linus Chuang MD MPH MS Professor, Gynecologic Oncology Icahn School of Medicine at Mount Sinai New York NY 84% of incidence and death occur in

More information

Quimio Radioterapia en Cancer de Cervix

Quimio Radioterapia en Cancer de Cervix Quimio Radioterapia en Cancer de Cervix HIGINIA R. CÁRDENES PROFESSOR RADIATION ONCOLOGY CLINICAL DIRECTOR SCHNECK CANCER CENTER Worldwide incidence of cervical cancer 2014, 12.360 cases Global incidence

More information

Effectiveness of cervical cancer therapy using neoadjuvant chemotherapy in combination with radical surgery: a metaanalysis

Effectiveness of cervical cancer therapy using neoadjuvant chemotherapy in combination with radical surgery: a metaanalysis Original Article Effectiveness of cervical cancer therapy using neoadjuvant chemotherapy in combination with radical surgery: a metaanalysis Yijie Fu 1, Tianmin Zhu 2, Hui Li 3 1 Department of Internal

More information

Impact of Surgery Extent on Survival and Recurrence Rate of Stage ⅠEndometrial Adenocarcinoma

Impact of Surgery Extent on Survival and Recurrence Rate of Stage ⅠEndometrial Adenocarcinoma Hou et al. / Cancer Cell Research 3 (2014) 65-69 Cancer Cell Research Available at http:// http://www.cancercellresearch.org/ ISSN 2161-2609 Impact of Surgery Extent on Survival and Recurrence Rate of

More information

trial update clinical

trial update clinical trial update clinical by John W. Mucenski, BS, PharmD, Director of Pharmacy Operations, UPMC Cancer Centers The treatment outcome for patients with relapsed or refractory cervical carcinoma remains dismal.

More information

Efficacy and Toxicity of Neoadjuvant Chemotherapy Followed by Radiochemotherapy in Locally Advanced Cervical Cancer

Efficacy and Toxicity of Neoadjuvant Chemotherapy Followed by Radiochemotherapy in Locally Advanced Cervical Cancer original studies Efficacy and Toxicity of Neoadjuvant Chemotherapy Followed by Radiochemotherapy in Locally Advanced Cervical Cancer Nemes Adina 1, Nagy Viorica 1, 2, Todor Nicolae 1, Marita Andreea 1,

More information

Yukiharu Todo 1, Hidemichi Watari 2. Abstract

Yukiharu Todo 1, Hidemichi Watari 2. Abstract Review Article on Cervical Cancer Concurrent chemoradiotherapy for cervical cancer: background including evidence-based data, pitfalls of the data, limitation of treatment in certain groups Yukiharu Todo

More information

ENDOMETRIAL CANCER Updated Apr 2017 by: Dr. Jenny Ko (Medical Oncologist, Abbotsford Cancer Centre)

ENDOMETRIAL CANCER Updated Apr 2017 by: Dr. Jenny Ko (Medical Oncologist, Abbotsford Cancer Centre) ENDOMETRIAL CANCER Updated Apr 2017 by: Dr. Jenny Ko (Medical Oncologist, Abbotsford Cancer Centre) Source: UpToDate 2017, ASCO/CCO/Alberta provincial guidelines, NCCN Reviewed by: Dr. Sarah Glaze (Gynecologic

More information

North of Scotland Cancer Network Clinical Management Guideline for Carcinoma of the Uterine Cervix

North of Scotland Cancer Network Clinical Management Guideline for Carcinoma of the Uterine Cervix THIS DOCUMENT North of Scotland Cancer Network Carcinoma of the Uterine Cervix UNCONTROLLED WHEN PRINTED DOCUMENT CONTROL Prepared by A Kennedy/AG Macdonald/Others Approved by NOT APPROVED Issue date April

More information

An Unusual Case of Cervical Cancer with Inguinal Lymph Node Metastasis: A Case Report and Review of the Literature

An Unusual Case of Cervical Cancer with Inguinal Lymph Node Metastasis: A Case Report and Review of the Literature Archives of Clinical and Medical Case Reports doi: 10.26502/acmcr.9655003 Volume 1, Issue 1 Case Report An Unusual Case of Cervical Cancer with Inguinal Lymph Node Metastasis: A Case Report and Review

More information

The Effect of Treatment Time in Locally Advanced Cervical Cancer in the Era of Concurrent Chemoradiotherapy

The Effect of Treatment Time in Locally Advanced Cervical Cancer in the Era of Concurrent Chemoradiotherapy The Effect of Treatment Time in Locally Advanced Cervical Cancer in the Era of Concurrent Chemoradiotherapy Suisui Song, MD 1 ; Sonali Rudra, MD 1 ; Michael D. Hasselle, MD 2 ; Paige L. Dorn, MD 1 ; Loren

More information

Isolated Para-Aortic Lymph Nodes Recurrence in Carcinoma Cervix

Isolated Para-Aortic Lymph Nodes Recurrence in Carcinoma Cervix J Nepal Health Res Counc 2009 Oct;7(15):103-7 Original Article Isolated Para-Aortic Lymph Nodes Recurrence in Carcinoma Cervix Ghimire S 1, Hamid S, 2 Rashid A 2 1 Bhaktapur Cancer Hospital, Bhaktapur,

More information

ARROCase: Locally Advanced Endometrial Cancer

ARROCase: Locally Advanced Endometrial Cancer ARROCase: Locally Advanced Endometrial Cancer Charles Vu, MD (PGY-3) Faculty Advisor: Peter Y. Chen, MD, FACR Beaumont Health (Royal Oak, MI) November 2016 Case 62yo female with a 3yr history of vaginal

More information

Radiotherapy & Cervical Cancer Dr Mary McCormack Consultant Clinical Oncologist University College Hospital, London,UK

Radiotherapy & Cervical Cancer Dr Mary McCormack Consultant Clinical Oncologist University College Hospital, London,UK Lead Group Log Radiotherapy & Cervical Cancer Dr Mary McCormack Consultant Clinical Oncologist University College Hospital, London,UK Cervical Cancer treatment Treatment planning should be made on a multidisciplinary

More information

CURRENT STANDARD OF CARE IN NASOPHARYNGEAL CANCER

CURRENT STANDARD OF CARE IN NASOPHARYNGEAL CANCER CURRENT STANDARD OF CARE IN NASOPHARYNGEAL CANCER Jean-Pascal Machiels Department of medical oncology Institut I Roi Albert II Cliniques universitaires Saint-Luc Université catholique de Louvain, Brussels,

More information

Prognostic Impact of Histology in Patients with Cervical Squamous Cell Carcinoma, Adenocarcinoma and Small Cell Neuroendocrine Carcinoma

Prognostic Impact of Histology in Patients with Cervical Squamous Cell Carcinoma, Adenocarcinoma and Small Cell Neuroendocrine Carcinoma DOI:http://dx.doi.org/10.7314/APJCP.2013.14.9.5355 Prognostic Impact of Histology in Patients with Cervical Cancer RESEARCH ARTICLE Prognostic Impact of Histology in Patients with Cervical Squamous Cell

More information

Should the Optimal Adjuvant Treatment for Patients With Early-Stage Endometrial Cancer With High-Intermediate Risk Factors Depend on Tumor Grade?

Should the Optimal Adjuvant Treatment for Patients With Early-Stage Endometrial Cancer With High-Intermediate Risk Factors Depend on Tumor Grade? ORIGINAL STUDY Should the Optimal Adjuvant Treatment for Patients With Early-Stage Endometrial Cancer With High-Intermediate Risk Factors Depend on Tumor Grade? Chunyan Lan, MD,* Xin Huang, MD,* Qidan

More information

HYPERTHERMIA in CERVIX and VAGINA CANCER. J. van der Zee

HYPERTHERMIA in CERVIX and VAGINA CANCER. J. van der Zee HYPERTHERMIA in CERVIX and VAGINA CANCER J. van der Zee ESTRO 2006 Deep hyperthermia in Rotterdam HYPERTHERMIA in CERVIX and VAGINA CANCER ESTRO 2006 Hyperthermia and radiotherapy in primary advanced cervix

More information

Invasive Cervical Cancer: Squamous Cell, Adenocarcinoma, Adenosquamous

Invasive Cervical Cancer: Squamous Cell, Adenocarcinoma, Adenosquamous Note: If available, clinical trials should be considered as preferred treatment options for eligible patients (www.mdanderson.org/gynonctrials). Other co-morbidities are taken into consideration prior

More information

SCIENTIFIC PAPER ABSTRACT INTRODUCTION PATIENTS AND METHODS

SCIENTIFIC PAPER ABSTRACT INTRODUCTION PATIENTS AND METHODS SCIENTIFIC PAPER Laparoscopic Transperitoneal Infrarenal Para-Aortic Lymphadenectomy in Patients with FIGO Stage IB1-II B Cervical Carcinoma Dae G. Hong, MD, PhD, Nae Y. Park, MD, Gun O. Chong, MD, Young

More information

Adjuvant Chemotherapy in High Risk Patients after Wertheim Hysterectomy 10-year Survivals

Adjuvant Chemotherapy in High Risk Patients after Wertheim Hysterectomy 10-year Survivals 6 Adjuvant Chemotherapy in High Risk Patients after Wertheim Hysterectomy 0-year Survivals V Sivanesaratnam,*FAMM, FRCOG, FACS Abstract Although the primary operative mortality following radical hysterectomy

More information

Comparative Efficacy of Cisplatin vs. Gemcitabine as Concurrent Chemotherapy for Untreated Locally Advanced Cervical Cancer: A Randomized Trail

Comparative Efficacy of Cisplatin vs. Gemcitabine as Concurrent Chemotherapy for Untreated Locally Advanced Cervical Cancer: A Randomized Trail Comparative Efficacy of Cisplatin vs. Gemcitabine as Concurrent Chemotherapy for Untreated Locally Advanced Cervical Cancer: A Randomized Trail Dr. Nishee Srivastava MD, Dr. Kamal Sahani MD, Dr. Manoj

More information

Comparison of Quality of Life and Sexuality between Cervical Cancer Survivors and Healthy Women

Comparison of Quality of Life and Sexuality between Cervical Cancer Survivors and Healthy Women pissn 1598-2998, eissn 2005-9256 Cancer Res Treat. 2016;48(4):1321-1329 Original Article http://dx.doi.org/10.4143/crt.2015.425 Open Access Comparison of Quality of Life and Sexuality between Cervical

More information

AOGS MAIN RESEARCH ARTICLE

AOGS MAIN RESEARCH ARTICLE A C TA Obstetricia et Gynecologica AOGS MAIN RESEARCH ARTICLE Differential clinical characteristics, treatment response and prognosis of locally advanced adenocarcinoma/ adenosquamous carcinoma and squamous

More information

Extrafascial hysterectomy after concurrent chemoradiotherapy in locally advanced cervical adenocarcinoma

Extrafascial hysterectomy after concurrent chemoradiotherapy in locally advanced cervical adenocarcinoma J Gynecol Oncol. 2016 Jul;27(4):e40 pissn 2005-0380 eissn 2005-0399 Original Article Extrafascial hysterectomy after concurrent chemoradiotherapy in locally advanced cervical adenocarcinoma Jie Yang, Keng

More information

Present status and future direction of clinical trials in advanced endometrial carcinoma

Present status and future direction of clinical trials in advanced endometrial carcinoma J Gynecol Oncol Vol. 9, No. 3:57-6, September 8 DOI:.38/jgo.8.9.3.57 Review Article Present status and future direction of clinical trials in advanced endometrial carcinoma Division of Gynecologic Oncology,

More information

pros and cons

pros and cons A Gynecologic Oncology Group Study Randomized Phase III Trial of Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: v.s. III GOG Marcus E. Randall,

More information

Is Prophylactic Irradiation to Para-aortic Lymph Nodes in Locally Advanced Cervical Cancer Necessary?

Is Prophylactic Irradiation to Para-aortic Lymph Nodes in Locally Advanced Cervical Cancer Necessary? pissn 1598-2998, eissn 2005-9256 Cancer Res Treat. 2014;46(4):374-382 Original Article http://dx.doi.org/10.4143/crt.2013.084 Open Access Is Prophylactic Irradiation to Para-aortic Lymph Nodes in Locally

More information

BEATcc Trial: ENGOT-Cx10 / GEICO 68-C / JGOG1084. GCIG Meeting

BEATcc Trial: ENGOT-Cx10 / GEICO 68-C / JGOG1084. GCIG Meeting BEATcc Trial: ENGOT-Cx10 / GEICO 68-C / JGOG1084 GCIG Meeting Ana Oaknin, MD PhD Head of Gynecologic Cancer Program. Vall d Hebron Institute of Oncology(VHIO). Vall d Hebron University Hospital. GEICO

More information

Cost-utility analysis of treatments for stage IB cervical cancer

Cost-utility analysis of treatments for stage IB cervical cancer Original Article J Gynecol Oncol Vol. 25, No. 2:97-104 pissn 2005-0380 eissn 2005-0399 Cost-utility analysis of treatments for stage IB cervical cancer Kanyarat Katanyoo 1, Naiyana Praditsitthikorn 2,

More information

Correspondence should be addressed to Dae Sik Yang;

Correspondence should be addressed to Dae Sik Yang; Hindawi BioMed Research International Volume 2017, Article ID 2917925, 9 pages https://doi.org/10.1155/2017/2917925 Clinical Study Validation of Nomograms for Survival and Metastases after Hysterectomy

More information

Analysis of Prognosis and Prognostic Factors of Cervical Adenocarcinoma and Adenosqumous Carcinoma of the Cervix

Analysis of Prognosis and Prognostic Factors of Cervical Adenocarcinoma and Adenosqumous Carcinoma of the Cervix DOI 10.1007/s11805-009-0133-8 133 Analysis of rognosis and rognostic Factors of Cervical Adenocarcinoma and Adenosqumous Carcinoma of the Cervix Guangwen Yuan Lingying Wu Xiaoguang Li Manni Huang Department

More information

ACR Appropriateness Criteria Role of Adjuvant Therapy in the Management of Early Stage Cervical Cancer EVIDENCE TABLE

ACR Appropriateness Criteria Role of Adjuvant Therapy in the Management of Early Stage Cervical Cancer EVIDENCE TABLE 1. Koehler C, Gottschalk E, Chiantera V, Marnitz S, Hasenbein K, Schneider A. From laparoscopic assisted radical vaginal hysterectomy to vaginal assisted laparoscopic radical hysterectomy. BJOG. 01;119():5-6..

More information

Prof. Dr. Aydın ÖZSARAN

Prof. Dr. Aydın ÖZSARAN Prof. Dr. Aydın ÖZSARAN Adenocarcinomas of the endometrium Most common gynecologic malignancy in developed countries Second most common in developing countries. Adenocarcinomas, grade 1 and 2 endometrioid

More information

Risk group criteria for tailoring adjuvant treatment in patients with endometrial cancer : a validation study of the GOG criteria

Risk group criteria for tailoring adjuvant treatment in patients with endometrial cancer : a validation study of the GOG criteria Risk group criteria for tailoring adjuvant treatment in patients with endometrial cancer : a validation study of the GOG criteria Suk-Joon Chang, MD, Hee-Sug Ryu MD Gynecologic Cancer Center Department

More information

Tae-Wook Kong 1,2, Joo-Hyuk Son 1,2, Jiheum Paek 1,2, Yonghee Lee 1,3, Eun Ju Lee 1,4, Suk-Joon Chang 1,2, Hee-Sug Ryu 1,2

Tae-Wook Kong 1,2, Joo-Hyuk Son 1,2, Jiheum Paek 1,2, Yonghee Lee 1,3, Eun Ju Lee 1,4, Suk-Joon Chang 1,2, Hee-Sug Ryu 1,2 Preoperative nomogram for individualized prediction of parametrial invasion in patients with FIGO stage IB cervical cancer treated with radical hysterectomy Tae-Wook Kong 1,2, Joo-Hyuk Son 1,2, Jiheum

More information

Neoadjuvant and postoperative chemotherapy with paclitaxel plus cisplatin for the treatment of FIGO stage IB cervical cancer in pregnancy

Neoadjuvant and postoperative chemotherapy with paclitaxel plus cisplatin for the treatment of FIGO stage IB cervical cancer in pregnancy Case Report Obstet Gynecol Sci 2014;57(6):539-543 http://dx.doi.org/10.5468/ogs.2014.57.6.539 pissn 2287-8572 eissn 2287-8580 Neoadjuvant and postoperative chemotherapy with paclitaxel plus cisplatin for

More information

An Alternative Triage Strategy Based on Preoperative MRI for Avoiding Trimodality Therapy in Stage IB Cervical Cancer

An Alternative Triage Strategy Based on Preoperative MRI for Avoiding Trimodality Therapy in Stage IB Cervical Cancer pissn 1598-2998, eissn 2005-9256 Cancer Res Treat. 2016;48(1):259-265 Original Article http://dx.doi.org/10.4143/crt.2014.370 Open Access An Alternative Triage Strategy Based on Preoperative MRI for Avoiding

More information

ONCOLOGY REPORTS 19: , 2008

ONCOLOGY REPORTS 19: , 2008 ONCOLOGY REPORTS 19: 1551-1556, 2008 A phase II multicenter trial of concurrent chemoradiotherapy with weekly nedaplatin in advanced uterine cervical carcinoma: Tohoku Gynecologic Cancer Unit Study YOSHIHITO

More information

PDF hosted at the Radboud Repository of the Radboud University Nijmegen

PDF hosted at the Radboud Repository of the Radboud University Nijmegen PDF hosted at the Radboud Repository of the Radboud University ijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/26054

More information

Non commercial use only. The role of neoadjuvant chemotherapy in the management of locally advanced cervix cancer: a systematic review

Non commercial use only. The role of neoadjuvant chemotherapy in the management of locally advanced cervix cancer: a systematic review Oncology Reviews 2014; volume 8:250 The role of neoadjuvant chemotherapy in the management of locally advanced cervix cancer: a systematic review Mohammed Osman Oncology Consultant, General Organization

More information

Prognostic Impact of Hyperglycemia in Patients with Locally Advanced Squamous Cell Carcinoma of Cervix Receiving Definite Radiotherapy

Prognostic Impact of Hyperglycemia in Patients with Locally Advanced Squamous Cell Carcinoma of Cervix Receiving Definite Radiotherapy Prognostic Impact of Hyperglycemia in Patients with Locally Advanced Squamous Cell Carcinoma of Cervix Receiving Definite Radiotherapy 2016.04.08 KCCH 김문홍 DM and prediabetes in cancer Negative impact on

More information

SLN Mapping in Cervical Cancer. Memorial Sloan Kettering Cancer Center New York, USA

SLN Mapping in Cervical Cancer. Memorial Sloan Kettering Cancer Center New York, USA Lead Grou p Log SLN Mapping in Cervical Cancer Nadeem R. Abu-Rustum, M.D. Memorial Sloan Kettering Cancer Center New York, USA Conflict of Interest Disclosure Nadeem R. Abu-Rustum, M.D. I have no financial

More information

Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer

Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer Find Studies About Studies Submit Studies Resources About Site Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer The safety and scientific validity of this study is

More information

Long-term results of early adjuvant concurrent chemoradiotherapy for highrisk, early stage uterine cervical cancer patients after radical hysterectomy

Long-term results of early adjuvant concurrent chemoradiotherapy for highrisk, early stage uterine cervical cancer patients after radical hysterectomy Kim et al. BMC Cancer (2017) 17:297 DOI 10.1186/s12885-017-3299-0 RESEARCH ARTICLE Open Access Long-term results of early adjuvant concurrent chemoradiotherapy for highrisk, early stage uterine cervical

More information

J Clin Oncol 22: by American Society of Clinical Oncology INTRODUCTION

J Clin Oncol 22: by American Society of Clinical Oncology INTRODUCTION VOLUME 22 NUMBER 5 MARCH 1 2004 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Pelvic Irradiation With Concurrent Chemotherapy Versus Pelvic and Para-Aortic Irradiation for High-Risk Cervical

More information

Para-aortic laparoscopic lymph-node dissection for advanced cervical cancers

Para-aortic laparoscopic lymph-node dissection for advanced cervical cancers Para-aortic laparoscopic lymph-node dissection for advanced cervical cancers P. Mathevet, Hôpital Femme-Mère-Enfant, Bron Lymph-node involvement Is one of the major prognostic factor in gynecologic cancers.

More information

Epidemiologic characteristics of cervical cancer in Korean women

Epidemiologic characteristics of cervical cancer in Korean women Review Article J Gynecol Oncol Vol. 25, No. 1:70-74 pissn 2005-0380 eissn 2005-0399 Epidemiologic characteristics of cervical cancer in Korean women Hyun-Joo Seol, Kyung-Do Ki, Jong-Min Lee Department

More information

Ovarian Transposition for Stage Ib Squamous Cell Cervical Cancer - Lack of Effects on Survival Rates?

Ovarian Transposition for Stage Ib Squamous Cell Cervical Cancer - Lack of Effects on Survival Rates? DOI:http://dx.doi.org/10.7314/APJCP.2013.14.1.133 RESEARCH ARTICLE Ovarian Transposition for Stage Ib Squamous Cell Cervical Cancer - Lack of Effects on Survival Rates? A Taner Turan 1, H Levent Keskin

More information

9. The role of cytoreductive surgery in cervical cancer: Is there a benefit of retroperitoneal lymph node debulking in advanced disease?

9. The role of cytoreductive surgery in cervical cancer: Is there a benefit of retroperitoneal lymph node debulking in advanced disease? Transworld Research Network 37/661 (2), Fort P.O. Trivandrum-695 023 Kerala, India Cytoreductive Surgery in Gynecologic Oncology: A Multidisciplinary Approach, 2010: 161-172 ISBN: 978-81-7895-484-4 Editor:

More information

September 10, Dear Dr. Clark,

September 10, Dear Dr. Clark, September 10, 2015 Peter E. Clark, MD Chair, NCCN Bladder Cancer Guidelines (Version 2.2015) Associate Professor of Urologic Surgery Vanderbilt Ingram Cancer Center Nashville, TN 37232 Dear Dr. Clark,

More information

Comparison of Three-Dimensional Conformal Radiotherapy and Intensity-Modulated Radiation Therapy ORIGINAL STUDY

Comparison of Three-Dimensional Conformal Radiotherapy and Intensity-Modulated Radiation Therapy ORIGINAL STUDY ORIGINAL STUDY Association Between Bone Marrow Dosimetric Parameters and Acute Hematologic Toxicity in Cervical Cancer Patients Undergoing Concurrent Chemoradiotherapy Comparison of Three-Dimensional Conformal

More information